Abbott Laboratories has entered into a licensing agreement with India’s Zydus Cadila to market the company’s products in 15 emerging countries.

The move, which will accelerate Abbot’s growth in emerging markets, will help the company gain the rights to at least 24 Zydus products, as well as an option to add a further 40 products.

The collaboration includes access to drugs for pain, cancer, neurological and cardiovascular illnesses, and will leverage off Abbot’s infrastructure to promote Zydus’s large portfolio.

Abbot also announced the creation of a new stand-alone Established Products Division with $5bn in current pharmaceutical sales that will focus solely on fast-growing emerging markets.

The financial terms of the agreement were not disclosed.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.